Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Diffuse large b-cell lymphoma recurrent? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 0.1% of all adverse event reports for BRENTUXIMAB VEDOTIN.

8
Reports of Diffuse large b-cell lymphoma recurrent with BRENTUXIMAB VEDOTIN
0.1%
of all BRENTUXIMAB VEDOTIN reports
0
Deaths
0
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma recurrent From BRENTUXIMAB VEDOTIN?

Of the 8 reports.

Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?

RITUXIMAB (1,359) CYCLOPHOSPHAMIDE (1,007) VINCRISTINE (957) DOXORUBICIN (953) PREDNISONE (738) CYTARABINE (406) DEXAMETHASONE (402) ETOPOSIDE (375) CISPLATIN (306) GEMCITABINE (280)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Diffuse large b-cell lymphoma recurrent Reports All Drugs Causing Diffuse large b-cell lymphoma recurrent BRENTUXIMAB VEDOTIN Demographics